iiinova — where your digital self keeps evolving

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14h

On #TAMO in 2025 How can AR-targeted therapy move beyond resistance in #prostate cancer? Emerging strategies (i.e. CYP11A1 inhibition/AR degraders/EZH2 inhibitors) are explored in this comprehensive review. @alicebernardt journals.sagepub.com/doi/10.1177/...

000

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 28/09/2026

🩸 How can a lipid–endothelial #signature stratify patients with #HCC? Luxi Yang et al. explore this through an integrated multi-omics approach, linking a six-gene signature with prognosis and immune-excluded features in HCC. 🔗 buff.ly/YnGZpEo

001

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 25/09/2026

On #TAMO in 2025 🤰 Fertility preservation is a key component of care for young patients with #breast #cancer. Interesting evidence in this RW cohort where 54% underwent cryopreservation. More details here: journals.sagepub.com/doi/full/10.... @matteolambe

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 23/09/2026

Evidence in NUT #carcinoma remains limited. This retrospective series of 25 H&N offers interesting insights into histologic differentiation and prognosis, including the adverse prognostic association of neuroendocrine differentiation. buff.ly/Evhy0A9

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 18/09/2026

On #TAMO in 2025. . End-of-life care is crucial in pancreatic #cancer. In this French cohort, 41% of pts received high-intensity EOL care, while #palliativecare involvement was associated with lower care intensity. . 👉 buff.ly/PyI4jy2

021

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 15/09/2026

Management of #testicular #cancer still diverges from guidelines. Adj treatment remains common in stage I disease despite surveillance-based recommendations, while repeat imaging in stage IIA is inconsistently used. More details 👉️ buff.ly/3oeKQLu #oncology #realworld

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 10/09/2026

On #TAMO in 2025 💊 🫁 🧬 Real-world evidence on selpercatinib in RET-rearranged #NSCLC is limited. In this updated analysis of LIBRETTO-321, selpercatinib showed durable responses, prolonged survival, and a good safety profile in Chinese patients. journals.sagepub.com/doi/full/10....

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 07/09/2026

Are T-cell engagers ready to reshape the #treatment of solid #tumors? This review summarizes current evidence on their safety profile and AE management, key challenges in clinical practice. journals.sagepub.com/doi/full/10.... #TAMO #oncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 03/09/2026

On #TAMO in 2025. . In a retrospective 20-center study, a depth of response ≥15% independently predicted longer PFS in pre-treated BRAFV600E #mCRC receiving encorafenib + cetuximab ± binimetinib. Read more: journals.sagepub.com/doi/full/10.... @Guv_onc @ChiaraCrem1 #colorectal #cancer

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 30/08/2026

How are new treatment options reshaping #ovarian #cancer care? In this review, @anacveneziani et al. focus on platinum-resistant disease and the emerging therapeutic strategies expanding treatment options for these patients. . buff.ly/CinYlnU #oncology #research #TAMO

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 28/08/2026

On #TAMO in #2025 . What is the impact of treatment-related deaths (TRDs) in #HNC pts treated with #CRT? A meta-analysis led by Gurizzani reported a 1.4% rate of TRDs, highlighting the need for careful pts selection and more intensive supportive care. buff.ly/IWinh1Z

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 26/08/2026

Online on #TAMO 👇🏽 With 1695 pts from 58 centers the Meet-URO 33–REGAL study shows an interesting real-world snapshot of #1L decision-making in #mRCC. journals.sagepub.com/doi/10.1177/... . @gbanna74 @rebuzzisara @meeturoIT

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 18/08/2026

#Nectin-4 is a key target for #ADCs in #urothelial carcinoma. This study evaluated Nectin-4 features in bladder #UC and #UTUC, revealing distinct expression patterns and associated immune contextures. buff.ly/vFzQdrH

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 21/07/2026

🚨 Call for Papers! Submit to our special collection on bladder-sparing strategies in urothelial carcinoma 🧪 Novel therapies & combinations 📈 Emerging clinical insights 👉 Learn more & submit: buff.ly/x5jNw3U #CallForPapers #Oncology #CancerResearch

032

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14/07/2026

📣 Call for Papers We’re inviting submissions for our special collection: Clinical Trials Driving Innovation in Oncology Share your latest research and help shape the future of cancer care. 🔗 Learn more & submit: buff.ly/bioqZyF #Oncology #ClinicalTrials #AcademicPublishing #CallForPapers

012

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 10/07/2026

📰 Do antibody–drug conjugates outperform docetaxel in previously treated advanced NSCLC? This systematic review & meta-analysis of RCTs explores efficacy and safety outcomes 👇 🔗 buff.ly/YzcZqhm #Oncology #LungCancer #NSCLC #CancerResearch #ClinicalTrials

031

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 07/07/2026

🧪 Can a simple blood-based marker help predict treatment response in ESCC? This multicenter real-world study evaluates PIV in patients receiving neoadjuvant chemotherapy combined with anti–PD-1 therapy. 🔗 buff.ly/XjR59n1 #Oncology #Biomarkers #Immunotherapy

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 03/07/2026

📘 Evidence for post-progression strategies in HER2+ metastatic #BreastCancer with brain metastases remains limited. This multicenter real-world study adds insight into pyrotinib treatment beyond progression and rechallenge: buff.ly/0sbfEcd #ClinicalResearch

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 30/06/2026

🆕 Can genotype-guided dosing improve outcomes in metastatic #colorectalcancer? This phase II RCT explores regorafenib + FOLFIRI with UGT1A1-guided irinotecan escalation👇 🔗 journals.sagepub.com/doi/full/10.... #Oncology #ClinicalTrials #PrecisionMedicine

031

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 26/06/2026

📢Can a simple blood-based marker predict outcomes to #immunotherapy? This study explores how the pretreatment NLR relates to immune checkpoint inhibitor response in advanced #NSCLC with liver metastases. 🔗 Read more: buff.ly/osVDOYL #LungCancer #CancerResearch #Biomarkers

042

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 25/06/2026

Cytokine release syndrome (CRS) isn’t just a challenge in hematologic cancers -it’s increasingly relevant in solid tumours. This review dives into mechanism-driven strategies for prevention and management. 📖 buff.ly/ZDar0oT #Oncology #Immunotherapy #CancerResearch #ClinicalInsights

032

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 23/06/2026

🧬 Review on Solitary Fibrous Tumour explores histology, behaviour, risk assessment & treatment strategies. Stay ahead with the latest insights 👇 🔗 buff.ly/Yzeri1f #Oncology #Pathology #CancerResearch

021

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 21/06/2026

📊 IF 4.1 for Therapeutic Advances in Medical Oncology 🎉 Consistent, high-quality research in oncology - 📚 Start reading: journals.sagepub.com/home/tam #ImpactFactor #OncologyResearch

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 19/06/2026

🔬Research shows how virtual multiplex immunofluorescence can identify lymphocyte subsets that predict response to neoadjuvant therapy - advancing precision oncology. Read more: buff.ly/PvVYaEX #Oncology #CancerResearch #Immunology #PrecisionMedicine

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 16/06/2026

📣 Call for Papers – Submit to our Special Collection on: Tumor Microenvironment in GI Cancers 🔬 Focus: clinically actionable biomarkers & therapeutic insights 📊 Clinical + translational research encouraged 🗓 Deadline: 15 March 2027 👉 buff.ly/dpUqDMk #CallForPapers #PrecisionOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 12/06/2026

🆕 Nationwide real‑world data reveal how treatment gaps are linked to survival outcomes in #HepatocellularCarcinoma, highlighting unmet needs in routine care. 🔗 buff.ly/BF3QeGz #HCC #LiverCancer #CancerOutcomes #RealWorldEvidence

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 05/06/2026

🆕 This study explores afatinib dose optimization to improve outcomes while reducing toxicities in advanced EGFR‑mutated NSCLC patients in Vietnam. 🔗 buff.ly/XucLdR2 #LungCancer #NSCLC #EGFR #TargetedTherapy #Oncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 02/06/2026

📢 This phase Ib/II study investigates the addition of neoadjuvant neratinib to standard therapy in patients with inflammatory #breastcancer, including those with HER2+ and HR+/HER2‑ disease across stage III and IV settings. 👉 Read the full article: buff.ly/bFwUuVM #InflammatoryBreastCancer #HER2 #

021

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 29/05/2026

🆕 A multicenter phase II randomized trial evaluates Endostar + concurrent chemoradiotherapy in locally advanced cervical cancer. 🔗 Read the full article: buff.ly/mQhOTsg #CervicalCancer #OncologyResearch #ClinicalTrials #Radiotherapy

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 26/05/2026

🚨 Call for Papers The KRAS era is here - now we need strategies to anticipate & overcome resistance in pancreatic cancer. Submit by Mar 1, 2027: KRAS pathways, combos, resistance mechanisms, new targets & models. 🔗 buff.ly/eMwzb2N #PDAC #KRAS #TargetedTherapy #CancerResearch

021

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 22/05/2026

A large French multicenter cohort study examines how age influences clinical characteristics, treatment patterns, and outcomes in #BiliaryTractCancer, highlighting differences in unresectable disease and comparable survival after resection. buff.ly/6PIVm3G #Cholangiocarcinoma #GeriatricOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 19/05/2026

📣 Call for Papers A Collection in Ther Adv Med Oncol focuses on #ADCs in gynecologic cancers, including ovarian, endometrial, and cervical malignancies. We welcome clinically relevant research and reviews. 🗓️ Deadline: 26 Feb 2027 buff.ly/30K8r13 #GynecologicOncology #CancerResearch #OpenCall

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 12/05/2026

We invites submissions to the Collection “Advances in Acute Myeloid Leukemia (AML) Therapy in the Precision Medicine Era.” Submission deadline: 19 Feb 2027 buff.ly/xsqkygl #AML #PrecisionOncology #HematologicMalignancies #MRD

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 08/05/2026

A study across Brazil, Mexico, and Peru examines how fertility concerns influence acceptance of (neo)adjuvant chemotherapy among young women with early-stage #BreastCancer, highlighting gaps in awareness and access to fertility preservation. buff.ly/W1gWits #OncoFertility #CancerCare #LatinAmerica

011

Reposted by Therapeutic Advances in Medical Oncology

Jen L, PhD @drjkyl.bsky.social · 06/05/2026

📣 If you will be at #ESTRO26 please connect with my team member Applonia! She is alsI Editor of the journal Technology in Cancer Research & Treatment which has a significant focus on radiation oncology research. #oncosky #oncology #radiotherapy #ESTRO2026

021

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 05/05/2026

📣 Call for Papers - Volume 2 Following the success of Volume 1, Ther Adv Med Oncol launches Volume 2 of this Collection on #ADC in #BreastCancer, focusing on new standards, emerging challenges, and future directions. Deadline: 29 Jan 2027 journals.sagepub.com/topic/collec... #MedicalOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 01/05/2026

Resistance to second‑generation AR pathway inhibitors remains a key challenge in #ProstateCancer. This review explores mechanisms of resistance and emerging third‑generation strategies, including AR degraders and steroid biosynthesis inhibitors. buff.ly/dDwk7Tz #AndrogenReceptor #PrecisionOncology

031

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 28/04/2026

Call for papers: a new collection in Ther Adv Med Oncol focuses on immunotherapy for T‑cell malignancies, spanning checkpoint inhibition, ADCs, bispecifics, cellular therapies, biomarkers, and resistance mechanisms. buff.ly/y2kbSVy #HematologicMalignancies #Immunotherapy #TCellLymphoma

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 24/04/2026

Genomic profiling is reshaping research strategies in cervical, vulvar & vaginal cancers. This review summarises molecular features across tumour types and examines emerging targeted and combination approaches, including #ADC. buff.ly/EP7cYS5 #GynOnc #PrecisionOncology #CancerGenomics

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 21/04/2026

A new Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are shaping lung cancer care across the disease continuum. Deadline: 29 Jan 2027 buff.ly/RrkerAu #LungCancer #PrecisionOncology #Biomarkers #MedicalOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 17/04/2026

#ADCs are reshaping breast oncology, alongside new questions on sequencing, biomarkers, and toxicity management. Explore this Ther Adv Med Oncol special collection, guest edited by Paolo Tarantino, MD, and Ilana Schlam, MD. buff.ly/pZycpW5 #BreastCancer #ADCs #MedicalOncology #OncologyResearch

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14/04/2026

A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need. Submission deadline: 14 Dec 2026 buff.ly/Da8ENXI #HRpositive #HER2negative #MedicalOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 10/04/2026

A real‑world retrospective study in Ther Adv Med Oncol examined the prevalence of HER2‑ultralow disease in HR+/HER2‑negative metastatic breast cancer and reported comparable first‑line chemotherapy outcomes to HER2‑low disease. buff.ly/Q7JaadR #BreastCancer #HER2 #MedicalOncology #RealWorldEvidence

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 07/04/2026

Ther Adv Med Oncol announces an open call for a Special Collection on Advances in Clinical Care for Glioblastoma. We welcome clinically actionable research across the care pathway, from diagnostics to patient‑centered outcomes. buff.ly/8jRyYqj #Glioblastoma #NeuroOncology #MedicalOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 03/04/2026

A dual‑center study in Ther Adv Med Oncol evaluated the Systemic Inflammation‑Nutrition Index (SINI) as a predictor of pathological response and relapse‑free survival in locally advanced #GIST treated with neoadjuvant imatinib. buff.ly/fKecUtx #Sarcoma #MedicalOncology #TargetedTherapy

021

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 31/03/2026

Ther Adv Med Oncol announces an open call for a Special Collection on Modern Approaches to Patient Selection in Breast Cancer. Submissions addressing biomarkers, computational tools, and integrated clinical strategies are welcome. buff.ly/t6TEH5G #BreastCancer #MedicalOncology #PrecisionOncology

011

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 27/03/2026

A dual‑center study evaluates the systemic inflammation–nutrition index (SINI) as a predictor of pathological response and prognosis in locally advanced #GIST treated with neoadjuvant imatinib. A SINI‑based nomogram showed strong discrimination. buff.ly/pvg142X #Sarcoma #Imatinib #Biomarkers

031